{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-023332","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.398710+00:00","generated_at":"2026-05-17T13:59:54.425025+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Indaptus reports Q2 net loss $9.09/sh; first patient dosed in Decoy20 combo trial with tislelizumab","bullets":["Q2 2025 R&D expenses $2.2M (up $0.5M YoY); G&A $2.3M (down $0.1M YoY); net loss per share $9.09 vs. $13.16.","Cash and equivalents $6.2M as of June 30, 2025; expected runway into Q4 2025.","First patient dosed in Phase 1b/2 combination study of Decoy20 with PD-1 checkpoint inhibitor tislelizumab (TEVIMBRA).","Raised ~$5.7M gross via convertible notes and warrants in June 2025; converted to common stock and pre-funded warrants in July.","Company expects to share initial combination trial data from first cohort later this year."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-023332","json":"https://secwatch.observer/filing/0001641172-25-023332.json","markdown":"https://secwatch.observer/filing/0001641172-25-023332.md","text":"https://secwatch.observer/filing/0001641172-25-023332.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000164117225023332/0001641172-25-023332-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000164117225023332/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:59:54.425025+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}